Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung Cancer

• Published in: Anticancer research Vol. 31; no. 12; pp. 4519 - 4523
• Main Authors: INOMATA, Minehiko, SHUKUYA, Takehito, ENDO, Masahiro, YAMAMOTO, Nobuyuki, TAKAHASHI, Toshiaki, ONO, Akira, NAKAMURA, Yukiko, TSUYA, Asuka, KENMOTSU, Hirotsugu, NAITO, Tateaki, MURAKAMI, Haruyasu, HARADA, Hideyuki
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.12.2011
• Subjects: Adult; Aged; Antineoplastic agents; Biological and medical sciences; Bone Neoplasms - drug therapy; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Chemotherapy; Disease Progression; Disease-Free Survival; Enzyme Inhibitors - pharmacology; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Lung Neoplasms - radiotherapy; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Quinazolines - therapeutic use; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor, Epidermal Growth Factor - genetics; Retrospective Studies; Treatment Outcome; Tumors; Antineoplastic agent; Prognosis; Continuous; Quinazoline derivatives; Lung cancer; Diseases of the osteoarticular system; non-small cell lung carcinoma; Epidermal growth factor receptor; Cancerology; Bronchus disease; Gefitinib; Protein-tyrosine kinase; Human; Lung disease; Enzyme; Tyrosine kinase inhibitor; Respiratory disease; Transferases; Enzyme inhibitor; EGFR-TKIs; Malignant tumor; Radiotherapy; Survival; resistance; Chemotherapy; Bone metastasis; Treatment; Erlotinib; Non-small cell lung cancer; Cancer
• ISSN: 0250-7005; 1791-7530

There have been reports suggesting that continuous administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which disease progression was observed after the establishment of clinical benefit from EGFR-TKIs. We retrospectively evaluated the clinical course of patients who received continuous administration of EGFR-TKIs after disease progression was detected solely in bone lesions. The medical records of patients administered gefitinib or erlotinib between 2002 and 2010 were reviewed. We evaluated the progression-free survival (PFS) and overall survival (OS) in patients who had bone metastases after the establishment of clinical benefit from EGFR-TKI and who received radiation therapy for the bone lesion and continuous treatment with EGFR-TKI. Ten patients were enrolled in this study. The median PFS and OS were 88 days and 330 days, respectively. Furthermore, a longer duration from the start of first EGFR-TKI to detection of bone metastases (p=0.0049) was identified as being significantly associated with a longer PFS. Our data suggest that continuous administration of EGFR-TKI is a treatment option for patients with bone metastases who previously benefited from therapy with EGFR-TKI.